Abstract
Original language | English |
---|---|
Article number | 244 |
Pages (from-to) | 244 |
Journal | BMC medicine |
Volume | 20 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Dec 2022 |
Keywords
- Adults
- COVID-19
- COVID-19 sequelae
- Children
- Long COVID
- PASC
- Post-COVID-19 condition
- Post-acute sequelae of SARS-CoV-2 infection
- Prevalence
- Risk factor
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: BMC medicine, Vol. 20, No. 1, 244, 01.12.2022, p. 244.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge
T2 - a prospective, cohort study in Moscow (StopCOVID)
AU - Pazukhina, Ekaterina
AU - Andreeva, Margarita
AU - Spiridonova, Ekaterina
AU - Bobkova, Polina
AU - Shikhaleva, Anastasia
AU - el-Taravi, Yasmin
AU - Rumyantsev, Mikhail
AU - Gamirova, Aysylu
AU - Bairashevskaia, Anastasiia
AU - Petrova, Polina
AU - Baimukhambetova, Dina
AU - Pikuza, Maria
AU - Abdeeva, Elina
AU - Filippova, Yulia
AU - Deunezhewa, Salima
AU - Nekliudov, Nikita
AU - Bugaeva, Polina
AU - Bulanov, Nikolay
AU - Avdeev, Sergey
AU - Kapustina, Valentina
AU - Guekht, Alla
AU - DunnGalvin, Audrey
AU - Comberiati, Pasquale
AU - Peroni, Diego G.
AU - Apfelbacher, Christian
AU - Genuneit, Jon
AU - Reyes, Luis Felipe
AU - Brackel, Caroline L. H.
AU - Fomin, Victor
AU - Svistunov, Andrey A.
AU - Timashev, Peter
AU - Mazankova, Lyudmila
AU - Miroshina, Alexandra
AU - Samitova, Elmira
AU - Borzakova, Svetlana
AU - Bondarenko, Elena
AU - Korsunskiy, Anatoliy A.
AU - Carson, Gail
AU - Sigfrid, Louise
AU - Scott, Janet T.
AU - Greenhawt, Matthew
AU - Buonsenso, Danilo
AU - Semple, Malcolm G.
AU - Warner, John O.
AU - Olliaro, Piero
AU - Sechenov StopCOVID Research Team
AU - Needham, Dale M.
AU - Glybochko, Petr
AU - Butnaru, Denis
AU - Osmanov, Ismail M.
AU - Munblit, Daniel
N1 - Funding Information: We are very grateful to the Sechenov University Hospital Network and Z.A. Bashlyaeva Children’s Municipal Clinical Hospital clinical staff and to the patients, parents, carers and families for their kindness and understanding during these difficult times of COVID-19 pandemic. We would also like to thank UK Embassy in Moscow for providing a grant. We would like to express our very great appreciation to ISARIC Global COVID-19 follow-up working group for the survey development. We would like to thank Mr Maksim Kholopov for providing technical support in data collection and database administration. We are grateful to Daria Bessonova, Olga Burencheva, Natalia Chepelova, Natalia Gorbova, Rina Grigoryan, Sapiat Isaeva, Alena Khrapkova, Ildar Khusainov, Tatiana Kokorina, Margaret Kvaratskheliya, Daria Levina, Anna Lunicheva, Margarita Mikheeva, Elizaveta Mikhsin, Roman Movsisyan, Veronika Palchikova, Maxim Privalov, Tatiana Reznikova, Olga Sokova, Ivan Timchenko, Anna Zezyulina, and Mikhail Zhilinsky for their help at different stages of the project. We are very thankful to FLIP, Eat & Talk, Luch, Black Market, and Academia for providing us the workspace in time of need and their support of COVID-19 research. Finally, we would like to extend our gratitude to the Global ISARIC team, the ISARIC global adult and paediatric COVID-19 follow-up working group, and ISARIC Global support centre for their continuous support and expertise and for the development of the outbreak ready standardised protocols for the data collection. Sechenov StopCOVID Research Team: Nikol Alekseeva, Elena Artigas, Asmik Avagyan, Lusine Baziyants, Anna Belkina, Anna Berbenyuk, Tatiana Bezbabicheva, Vadim Bezrukov, Semyon Bordyugov, Aleksandra Borisenko, Maria Bratukhina, Ekaterina Bugaiskaya, Julia Chayka, Yulia Cherdantseva, Natalia Degtyareva, Olesya Druzhkova, Alexander Dubinin, Khalisa Elifkhanova, Dmitry Eliseev, Anastasia Ezhova, Aleksandra Frolova, Julia Ganieva, Anastasia Gorina, Cyrill Gorlenko, Elizaveta Gribaleva, Eliza Gudratova, Shabnam Ibragimova, Khadizhat Kabieva, Yulia Kalan, Margarita Kalinina, Nadezhda Khitrina, Bogdan Kirillov, Herman Kiseljow, Maria Kislova, Natalya Kogut, Irina Konova, Mariia Korgunova, Anastasia Kotelnikova, Karina Kovygina, Alexandra Krupina, Anastasia Kuznetsova, Anna Kuznetsova, Baina Lavginova, Elza Lidjieva, Ekaterina Listovskaya, Maria Lobova, Maria Loshkareva, Ekaterina Lyubimova, Daria Mamchich, Nadezhda Markina, Anastasia Maystrenko, Aigun Mursalova, Evgeniy Nagornov, Anna Nartova, Daria Nikolaeva, Georgiy Novoselov, Marina Ogandzhanova, Anna Pavlenko, Olga Perekosova, Erika Porubayeva, Kristina Presnyakova, Anna Pushkareva, Olga Romanova, Philipp Roshchin, Diana Salakhova, Ilona Sarukhanyan, Victoria Savina, Jamilya Shatrova, Nataliya Shishkina, Anastasia Shvedova, Denis Smirnov, Veronika Solovieva, Olga Spasskaya, Olga Sukhodolskaya, Shakir Suleimanov, Nailya Urmantaeva, Olga Usalka, Valeria Ustyan, Yana Valieva, Katerina Varaksina, Maria Varaksina Ekaterina Varlamova, Maria Vodianova, Margarita Yegiyan, Margarita Zaikina, Anastasia Zorina, Elena Zuykova. Funding Information: DM, DBu, and IMO conceptualised the project and formulated research goals and aims. EP, MA, ESp, PBo, PBu, NN, AS, YET, MR, AGa, AGu, NBu, SA, VK, and DM were responsible for the study design and methodology and participated in the overall project design discussions. ADG, PC, DGP, CA, JG, LFR, CLHB, GC, LS, JTS, MG, DaBu, MGS, JOW, PO, and DMN participated in the CRF development and/or provided expert input at different stages of the project. EP implemented the computer code and supporting algorithms and tested of existing code components. DM and EP tested hypotheses and discussed statistical analyses. EP performed statistical analysis. The StopCOVID Research Team, NN, PBu, MA, AGa, AS, AB, PP, DBa, MP, EA, YF, and SD conducted a research and investigation process, specifically performed data extraction, telephone interviews, and data collection. VF, AAS, PT, LM, AM, ESa, SB, EB, AAK, DM, DB, and PG provided study materials, access to patient data, laboratory data, and computing resources. MA, ESp, PBo, PBu, YET, and MR managed activities to annotate metadata and maintain research data for initial use and later reuse. EP prepared visualisation and worked under DM supervision on the data presentation. DM was responsible for the oversight and leadership for the research activity planning and execution. DM, DB, PBo, ES, AS, AG, and EP provided management and coordination for the research activity planning and execution. VF, AAS, PT, IMO, DB, PG, and DM were responsible for the acquisition of the financial support for the project leading to this publication. EP, NN, and DM wrote original draft. All the authors critically reviewed and commented on the manuscript draft at both, pre-and post-submission stages. All authors read and approved the final manuscript. Publisher Copyright: © 2022, The Author(s).
PY - 2022/12/1
Y1 - 2022/12/1
N2 - BACKGROUND: Previous studies assessing the prevalence of COVID-19 sequelae in adults and children were performed in the absence of an agreed definition. We investigated prevalence of post-COVID-19 condition (PCC) (WHO definition), at 6- and 12-months follow-up, amongst previously hospitalised adults and children and assessed risk factors. METHODS: Prospective cohort study of children and adults with confirmed COVID-19 in Moscow, hospitalised between April and August, 2020. Two follow-up telephone interviews, using the International Severe Acute Respiratory and Emerging Infection Consortium survey, were performed at 6 and 12 months after discharge. RESULTS: One thousand thirteen of 2509 (40%) of adults and 360 of 849 (42%) of children discharged participated in both the 6- and 12-month follow-ups. PCC prevalence was 50% (95% CI 47-53) in adults and 20% (95% CI 16-24) in children at 6 months, with decline to 34% (95% CI 31-37) and 11% (95% CI 8-14), respectively, at 12 months. In adults, female sex was associated with PCC at 6- and 12-month follow-up (OR 2.04, 95% CI 1.57 to 2.65) and (OR 2.04, 1.54 to 2.69), respectively. Pre-existing hypertension (OR 1.42, 1.04 to 1.94) was associated with post-COVID-19 condition at 12 months. In children, neurological comorbidities were associated with PCC both at 6 months (OR 4.38, 1.36 to 15.67) and 12 months (OR 8.96, 2.55 to 34.82) while allergic respiratory diseases were associated at 12 months (OR 2.66, 1.04 to 6.47). CONCLUSIONS: Although prevalence of PCC declined one year after discharge, one in three adults and one in ten children experienced ongoing sequelae. In adults, females and persons with pre-existing hypertension, and in children, persons with neurological comorbidities or allergic respiratory diseases are at higher risk of PCC.
AB - BACKGROUND: Previous studies assessing the prevalence of COVID-19 sequelae in adults and children were performed in the absence of an agreed definition. We investigated prevalence of post-COVID-19 condition (PCC) (WHO definition), at 6- and 12-months follow-up, amongst previously hospitalised adults and children and assessed risk factors. METHODS: Prospective cohort study of children and adults with confirmed COVID-19 in Moscow, hospitalised between April and August, 2020. Two follow-up telephone interviews, using the International Severe Acute Respiratory and Emerging Infection Consortium survey, were performed at 6 and 12 months after discharge. RESULTS: One thousand thirteen of 2509 (40%) of adults and 360 of 849 (42%) of children discharged participated in both the 6- and 12-month follow-ups. PCC prevalence was 50% (95% CI 47-53) in adults and 20% (95% CI 16-24) in children at 6 months, with decline to 34% (95% CI 31-37) and 11% (95% CI 8-14), respectively, at 12 months. In adults, female sex was associated with PCC at 6- and 12-month follow-up (OR 2.04, 95% CI 1.57 to 2.65) and (OR 2.04, 1.54 to 2.69), respectively. Pre-existing hypertension (OR 1.42, 1.04 to 1.94) was associated with post-COVID-19 condition at 12 months. In children, neurological comorbidities were associated with PCC both at 6 months (OR 4.38, 1.36 to 15.67) and 12 months (OR 8.96, 2.55 to 34.82) while allergic respiratory diseases were associated at 12 months (OR 2.66, 1.04 to 6.47). CONCLUSIONS: Although prevalence of PCC declined one year after discharge, one in three adults and one in ten children experienced ongoing sequelae. In adults, females and persons with pre-existing hypertension, and in children, persons with neurological comorbidities or allergic respiratory diseases are at higher risk of PCC.
KW - Adults
KW - COVID-19
KW - COVID-19 sequelae
KW - Children
KW - Long COVID
KW - PASC
KW - Post-COVID-19 condition
KW - Post-acute sequelae of SARS-CoV-2 infection
KW - Prevalence
KW - Risk factor
UR - http://www.scopus.com/inward/record.url?scp=85133568517&partnerID=8YFLogxK
U2 - https://doi.org/10.1186/s12916-022-02448-4
DO - https://doi.org/10.1186/s12916-022-02448-4
M3 - Article
C2 - 35794549
SN - 1464-2662
VL - 20
SP - 244
JO - BMC medicine
JF - BMC medicine
IS - 1
M1 - 244
ER -